[Treatment of initial cerebrovascular insufficiency with vincamine. Polycentric research on 828 cases].
The effect of vincamine on initial cerebrovascular insufficiency was examined by investigation of data relating to 828 patients from 11 centres. Most had received 6 tablets/day for 30 days. The method selected in gathering the data and their processing is described. Classic symptoms of initial insufficiency were considered after 7, 14, 21 and 30 days and evaluated along with a "seriousness" index relating to the symptomatology as a whole. The results pointed to continuous improvement in individual symptoms and overall from the outset of treatment, eventually leading to high remission percentages. Tolerance was generally good and very few cases of side-effects were reported.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000188:drug therapy*; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D014748:Vinca Alkaloids
Trattamento dell'insufficienza cerebro-vascolare iniziale con vincamina. Ricerca policentrica su 828 casi.